Erasca, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ERAS Nasdaq 2836 www.erasca.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Erasca, Inc.

Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% - May 29th, 2026 6:47 pm
Erasca to Present at the Jefferies Global Healthcare Conference - May 27th, 2026 6:00 am
Erasca Patent Dispute Puts ERAS-0015 And Investment Case Under Scrutiny - May 25th, 2026 6:19 pm
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade - May 20th, 2026 6:45 am
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally - May 18th, 2026 2:00 pm
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - May 17th, 2026 12:33 pm
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally - May 17th, 2026 12:25 pm
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More - May 17th, 2026 12:18 pm
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference - May 16th, 2026 1:05 pm
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy - May 16th, 2026 9:01 am
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma - May 14th, 2026 1:05 pm
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO - May 14th, 2026 12:57 pm
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% - May 14th, 2026 12:51 pm
How Investors Are Reacting To Erasca (ERAS) Wider Losses And Early Oncology Pipeline Efficacy Signs - May 12th, 2026 5:17 am
Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds - May 12th, 2026 4:07 am
Erasca Reports First Quarter 2026 Business Updates and Financial Results - May 11th, 2026 2:01 pm
Sector Update: Healthcare Stocks Softer Late Afternoon - May 11th, 2026 1:59 pm
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab) - May 11th, 2026 5:00 am
JPMorgan Recommends Buying Erasca (ERAS) Stock at Current Levels - May 10th, 2026 5:13 pm
Erasca Weighs ERAS-0015 Trial Progress Against Legal And Valuation Questions - May 7th, 2026 9:26 am